83490-20-4

Basic information

• Product Name: N-[(DIMETHYLAMINO)METHYLENE]THIOUREA
• Synonyms: N-[(DIMETHYLAMINO)METHYLENE]THIOUREA;1-((DIMETHYLAMINO)METHYLENE)THIOUREA;(E)-N'-carbamothioyl-N,N-dimethylformimidamide;N-[(E)-(Dimethylamino)methylidene]thiourea
• CAS NO: 83490-20-4
• Molecular Formula: C₄H₉N₃S
• Molecular Weight: 131.2
• Mol File: 83490-20-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 166 °C(Solv: ethanol (64-17-5))
• Boiling Point: 205.8°C at 760 mmHg
• Flash Point: 78.265°C
• Appearance: /
• Density: 1.133g/cm³
• Vapor Pressure: 0.245mmHg at 25°C
• Refractive Index: 1.549
• PKA: 14.53±0.29(Predicted)
• CAS DataBase Reference: N-[(DIMETHYLAMINO)METHYLENE]THIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(DIMETHYLAMINO)METHYLENE]THIOUREA(83490-20-4)
• EPA Substance Registry System: N-[(DIMETHYLAMINO)METHYLENE]THIOUREA(83490-20-4)

Safety Data

• Hazardous Substances Data: 83490-20-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C4H9N3S/c1-7(2)3-6-4(5)8/h3H,1-2H3,(H2,5,8)/b6-3+

Upstream product

• 17356-08-0 thiourea 
• 68-12-2 N,N-dimethyl-formamide 
• 1188-33-6 N,N-dimethylformamide diethyl diacetal 
• 5747-20-6 Dimethylaminoformaldehyd-dibutylmercaptal 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 38711-20-5 1,1-dimethoxymethyl-N,N-dimethylmethanamine 

Downstream Products

• 344361-86-0 4-(dimethylamino)-2-methylsulfanyl-1,3-diazabuta-1,3-dienium iodide 
• 53159-71-0 1-(2-aminothiazol-5-yl)ethanone 
• 27053-21-0 2-amino-5-(phenylcarbonyl)thiazole 
• 910297-67-5 N,N-dimethyl-N′-(tritylcarbamothioyl)formimidamide 

Relevant articles and documents

MRGPRX2 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present disclosure is directed to use of MrgprX2 antagonists in the treatment of inflammatory disorders, e.g., inflammatory disorders of the skin. This invention is also directed to pharmaceutical compositions comprising a MrgprX2 antagonist and a pha

Pharmacological investigation of quinoxaline-bisthiazoles as multitarget-directed ligands for the treatment of Alzheimer's disease

Alzheimer's disease (AD) is the most prevalent disease of old age leading to dementia. Complex AD pathogenesis involves multiple factors viz. amyloid plaque formation, neurofibrillary tangles and inflammation. Herein we report of a new series of quinoxaline-bisthiazoles as multitarget-directed ligands (MTDLs) targeting BACE-1 and inflammation concurrently. Virtual screening of a library of novel quinoxaline-bisthiazoles was performed by docking studies. The most active molecules from the docking library were taken up for synthesis and characterized by spectral data. Compounds 8a-8n showed BACE-1 inhibition in micro molar range. One of the compounds, 8n showed BACE-1 inhibition at IC50 of 3 ± 0.07 μM. Rat paw edema inhibition in acute and chronic models of inflammation were obtained at 69 ± 0.45% and 55 ± 0.7%, respectively. Compound 8n also showed noteworthy results in AlCl3 induced AD model. The treated rats exhibited excellent antiamnesic, antiamyloid, antioxidant, and neuroprotective properties. Behavioural parameters suggested improved cognitive functions which further validates the testimony of present study. Moreover, compound 8n was found to have inherent gastrointestinal safety. This new string of quinoxaline-bisthiazoles were identified as effective lead for the generation of potent MTDLs and compound 8n was found to showcase qualities to tackle AD pathogenesis.

Discovery, Development, and SAR of Aminothiazoles as LIMK Inhibitors with Cellular Anti-Invasive Properties

As part of a program to develop a small molecule inhibitor of LIMK, a series of aminothiazole inhibitors were discovered by high throughput screening. Scaffold hopping and subsequent SAR directed development led to a series of low nanomolar inhibitors of LIMK1 and LIMK2 that also inhibited the direct biomarker p-cofilin in cells and inhibited the invasion of MDA MB-231-luc cells in a matrigel inverse invasion assay.